Combining short-course radiotherapy with Raltitrexed and Tislelizumab for advanced esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the safety and efficacy of a treatment regimen that includes short-course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab for patients suffering from relapsed or advanced esophageal squamous cell carcinoma. The study focuses on patients who have experienced tumor recurrence after previous treatments or have regional progression of the disease. Participants will be monitored for their response to this combination therapy, assessing both safety and effectiveness in managing their condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signing informed consent; ECOG 0-2 points;
* Age over 18 years old, gender is not limited;
* Esophageal squamous cell carcinoma confirmed by pathology or clinically diagnosed by imaging;
* Recurrence of the tumor area after radical surgery or radical chemoradiotherapy; Regional progression of advanced esophageal squamous cell carcinoma after first-line or second-line treatment;
* Clinical staging: regional recurrence (rT0-4N0-3M0-1a) or regional progression (cT0-4N0-3M0-1) (AJCC/UICC esophageal cancer staging (8th edition));
* Tumor lesions can be evaluated;
* Expected survival ≥3 months;
* Major organ function is normal, meeting the following criteria: (i) blood routine examination A.HB ≥90g/L; b.ANC≥1.5×109/L; C. PLT ≥80×109/L; (ii) Biochemical examination: a. ALT/AST≤2.5ULN; b. TBIL≤1.5ULN; c. Plasma Cr≤1.5ULN or creatinine clearance (CCr)≥60ml/min;
* Women of childbearing age must have had a pregnancy within 7 days before starting treatment and the result is negative;
* All enrolled patients should take adequate contraceptive measures throughout the treatment period and 4 weeks after completion;
* no serious hematopoietic function, heart function, endocrine and immune function defects;
* No patients with grade 3 or above other serious medical diseases.

Exclusion Criteria:

* Under 18 years of age; ECOG is greater than 2;
* The diagnosis of esophageal cancer is not supported by pathological biopsy or image examination;
* Salvage surgery was performed after tumor recurrence;
* The patient has any active autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; The patient had vitiligo; Those with complete remission of asthma in childhood can be included without any intervention in adulthood; Patients with asthma requiring medical intervention with bronchodilators are not included);
* Patients who were taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes (doses \>10mg/ day of prednisone or other therapeutic hormones) and continued to use within 2 weeks before enrollment;
* Patients with severe and/or uncontrolled concomitant disease of grade 3 or higher, including: poor blood pressure control, myocardial ischemia or myocardial infarction, arrhythmia, active or uncontrolled severe infection; Liver diseases such as decompensated liver disease, active hepatitis B (HBV-DNA≥104 copy numbers /ml or 2000IU/ml), or hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower detection limit of analytical methods);
* Pregnant or lactating women;
* Patients who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
* Patients who have participated in clinical trials of other drugs within four weeks; .Patients or family members refused to participate in the study.

Where it's running

• Yuan He
  Hefei, China Recruiting

Study contacts

• Study coordinator: Yuan He, doctor
• Email: heyuan3766@126.com
• Phone: 800-555-5555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• Tislelizumab plus chemotherapy for advanced gastric, gastroesophageal, and esophageal squamous cancers in U.S. racial and ethnic minority patients

  This will test whether adding tislelizumab to standard chemotherapy helps U.S. racial and ethnic minority patients with HER2-negative, PD-L1-positive unresectable or metastatic gastric, gastroesophageal, or esophageal squamous cell cancer.

  Recruiting at 9 sites Phase 2 BeOne Medicines · Bullhead City, Arizona and 8 other locations · NCT07554521

• BL-B01D1 with Tislelizumab ± 5-FU as first-line treatment for unresectable, locally advanced recurrent, or metastatic esophageal squamous cell carcinoma

  A phase II/III trial tests BL-B01D1 with tislelizumab, with or without 5-FU, against standard platinum-based chemotherapy plus tislelizumab for adults with unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07554456

• Combining Tislelizumab and S-1 for Esophageal Cancer Treatment

  This study is testing a new combination of two drugs, Tislelizumab and S-1, to see if it can help patients with esophageal cancer who have had surgery and still have some cancer left.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT06354140

• Combining Tislelizumab with Chemotherapy for Esophageal Cancer Treatment

  This study is testing if combining a new immune therapy called tislelizumab with chemotherapy can help people with esophageal cancer live longer and stay cancer-free after surgery.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06056336

• Combining chemotherapy with Tislelizumab for esophageal cancer after surgery

  This study is testing if combining an immunotherapy drug called Tislelizumab with chemotherapy can help people with esophageal cancer live longer after surgery.

  Recruiting Phase 1 Affiliated Cancer Hospital of Shantou University Medical College · Shantou, Guangdong · NCT05984342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.